Pfizer’s COVID-19 Vaccine – BNT162b2 May Be Up To 40 Times Less Effective Against Omicron Variant


The first study on the effectiveness of the Pfizer’s COVID-19 vaccine (BNT162b2) against the new B.1.1.529 or Omicron variant by a laboratory at the Africa Health Research Institute in South Africa has revealed that the new variant can partially evade the protection from Pfizer Inc (PFE.N) and partner BioNTech’s COVID-19 vaccine.

Dr Alex Sigal, a professor at the Africa Health Research Institute, said on Twitter there was “a very large drop” in neutralization of the Omicron variant relative to an earlier strain of COVID.

The research laboratory tested blood from 12 people who had been vaccinated with the Pfizer/BioNTech vaccine.

The details of the study will be available on the laboratory’s site in the next 24 hours or so.

Premiminary paper found here.

The preprint manuscript version will be at MedRxiv in coming days.

The emergence of the Omicron variant (1) of SARS-CoV-2 in November 2021 in South Africa has raised concerns that, based on the large number of mutations in the spike protein and elsewhere on the virus (, this variant will have considerable escape from vaccine elicited immunity.

Furthermore, several mutations in the receptor binding domain and S2 are predicted to impact transmissibility and affinity for ACE-2.

Here we investigated whether Omicron escapes antibody neutralization elicited by the Pfizer BNT162b2 mRNA vaccine and whether the virus still requires binding to the ACE2 receptor to infect cells.

We used an early passage of isolated and sequence confirmed live Omicron virus isolated in South Africa.

We used a human lung cell line clone (H1299-ACE2) engineered to express the ACE2 receptor (2) to both isolate the virus and test neutralization. We also tested growth in the parental H1299 which do not overexpress ACE2 and are not appreciably infectable with SARS-CoV-2 (Fig S1).

The H1299-ACE2 cells were similar to Vero-E6 in titer dependent focus formation, but were considerably more sensitive (Fig S2). We observed that Omicron infected the ACE2-expressing cells in a concentration dependent manner but did not infect the parental H1299 cells, indicating that ACE2 is required for Omicron entry (Fig. 1A).

We then tested the ability of plasma from BNT162b2 vaccinated study participants to neutralize Omicron versus ancestral D614G virus in a live virus neutralization assay.

We tested 14 plasma samples from 12 participants (Table S1), with 6 having no previous record of SARS-CoV-2 infection nor detectable nucleocapsid antibodies indicative of previous infection. For two of these participants, we used samples from two timepoints.

The remaining 6 participants had a record of previous infection in the first SARS-CoV-2 infection wave in South Africa where infection was with ancestral D614G virus (Table S1). Geometric mean titer (GMT) FRNT50 (inverse of the plasma dilution required for 50% reduction in infection foci number) was 1321 for D614G.

These samples therefore had very strong neutralization of D614G virus, consistent with sampling soon after vaccination. GMT FRNT50 for the same samples was 32 for Omicron, a 41-fold decline (Fig 1B).

However, the escape was incomplete, with 5 of the participants, all previously infected, showing relatively high neutralization titers with Omicron.

Beta variant escape from BNT162b2 in a live virus neutralization assay has been reported to be substantial (3) and our own data confirmed these results (4), with about 3-fold reduction in FRNT50.

The results we present here with Omicron show much more extensive escape. However, escape was incomplete in participants with higher FRNT50 due to previous infection.

Previous infection, followed by vaccination or booster is likely to increase the neutralization level and likely confer protection from severe disease in Omicron infection.


1. Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ. 2021;375:n2943.

2. Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, Giandhari J, Pillay S, Wilkinson E, Naidoo Y, Karim F, Ganga Y, Khan K, Bernstein M, Balazs AB, Gosnell BI, Hanekom W, Moosa MS, Network for Genomic Surveillance in South A, Team C-K, Lessells RJ, de Oliveira T, Sigal A. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593(7857):142-6.

3. Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, Cai H, Sarkar R, Chen W, Cutler M. Neutralizing activity of BNT162b2-elicited serum. New England Journal of Medicine. 2021;384(15):1466-8.

4. Cele S, Karim F, Lustig G, James SE, Hermanus T, Wilkinson E, Snyman J, Bernstein M, Khan K, Hwa S-H, Tegally H, Tilles SW, Giandhari J, Mthabela N, Mazibuko M, Ganga Y, Gosnell BI, Karim SA, Hanekom W, Van Voorhis WC, Ndung’u T, Team C-K, Lessells RJ, Moore PL, Moosa M-YS, de Oliveira T, Sigal A. Divergence of delta and beta variants and SARS-CoV-2 evolved in prolonged infection into distinct serological phenotypes. medRxiv. 2021:2021.09.14.21263564.


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.